SCHEMBL2182082

SCHEMBL2182082

CCN(CC)CCNc1nnc2c(n1)c(=O)n(C)c(=O)n2-c1ccc(F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
TSHR P16473 5/20 0.40
HSD17B10 Q99714 5/20 0.40
KDM4E B2RXH2 3/20 0.40
CYP3A4 P08684 3/20 0.40
HPGD P15428 3/20 0.40
KAT2B Q92831 1/20 0.36
DCTPP1 Q9H773 1/20 0.36
TP53 P04637 3/20 0.36
LMNA P02545 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HTT P42858 1/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
USP2 O75604 2/20 0.35
CYP1A2 P05177 2/20 0.35
CASP1 P29466 2/20 0.35
CASP7 P55210 2/20 0.35
HIF1A Q16665 2/20 0.35
GLA P06280 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2179530 0.94 ALDH1A1 (0.36) ALDH1A1TSHRHSD17B10KDM4ECYP3A4
SCHEMBL2183482 0.94 ALDH1A1 (0.42) ALDH1A1TSHRHSD17B10KDM4ECYP3A4
SCHEMBL2181859 0.93 TSHR (0.36) ALDH1A1TSHRHSD17B10KDM4ECYP3A4
SCHEMBL2182806 0.90 ALDH1A1 (0.42) ALDH1A1TSHRHSD17B10KDM4EHPGD
SCHEMBL2183045 0.86 RAD52 (0.43) ALDH1A1TSHRHSD17B10KDM4ECYP3A4
SCHEMBL2185012 0.86 ALDH1A1 (0.41) ALDH1A1TSHRHSD17B10KDM4ECYP3A4
SCHEMBL2182838 0.85 DCTPP1 (0.38) ALDH1A1TSHRHSD17B10CYP3A4DCTPP1
SCHEMBL2181445 0.85 DCTPP1 (0.38) ALDH1A1TSHRHSD17B10DCTPP1TP53
SCHEMBL2180522 0.84 TSHR (0.35) ALDH1A1TSHRHSD17B10KDM4ECYP3A4
SCHEMBL2184364 0.84 ALDH1A1 (0.38) ALDH1A1TSHRHSD17B10KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181524-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2023-06-15 US disclosed
EP-4129282-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2023-02-08 EP disclosed
US-20110166144-A1 Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181524-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF TCF4, TCF7L2, CTNNB1 ALDH1A1 1526/4885TSHR 4571/4885HSD17B10 1725/4885
US-20110166144-A1 Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same DPYD, TYMP, DHFR ALDH1A1 245/4885TSHR 2089/4885HSD17B10 962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.